Advertisements

Diplexil 500

Quick links to important sections

Diplexil 500

Selected form

Advertisements

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Diplexil 500

Quick Facts

Property Description
Active Ingredient Valproic Acid (INN)
Pharmacological Class Anticonvulsant / Antiepileptic Drug (AED)
Origin Synthetic (Fatty acid derivative)
Common Forms Tablets, Capsules, Oral Solution
General Purpose Stabilizing nerve cell communication

What is Diplexil 500?

What is Diplexil 500 and What Type of Medicine is It?

Diplexil 500 is a pharmaceutical preparation containing the active ingredient Valproic Acid, often administered as a salt like Divalproex Sodium to enhance stability. This medication is classified as an Anticonvulsant, placing it within the category of Antiepileptic Drugs (AEDs). Valproic Acid is clinically recognized for its unique, broad-spectrum efficacy in moderating various forms of central nervous system overexcitation, distinguishing it from agents with narrower action profiles. The 500 mg strength indicates a standardized dose of the active compound.

Composition and Forms: Valproic Acid's Synthetic Origin

Valproic Acid is a synthetic compound, chemically defined as a branched short-chain fatty acid derivative. Its chemical structure grants it a distinctive multimodal mechanism which differentiates it from conventional AED classes. The medicine is supplied in various common dosage forms, including immediate, delayed, and extended-release tablets, capsules, and oral solutions. This range of forms offers flexibility in how the active ingredient is delivered, ensuring consistent control of the core valproate moiety.

General Purpose of Valproic Acid and its Function

The general therapeutic purpose of Valproic Acid is to help stabilize the nervous system by controlling excessive or uncontrolled neuronal excitation. Its fundamental function involves enhancing the effects of gamma-aminobutyric acid (GABA), the brain's main inhibitory neurotransmitter. This action of boosting the brain's natural calming signals is the key reason the drug is employed to achieve and maintain neurological stability.

Regulatory References

  1. NIH MeSH on Valproic Acid
Advertisements

What side effects are possible with Diplexil 500?

Possible Side Effects and Safety Information

The safety profile of Diplexil 500, containing Valproic Acid, is defined by regulatory documents based on frequency and severity across various organ systems. These classifications detail potential adverse reactions ranging from common to life-threatening serious events.

Frequency-Classified Adverse Reactions

The medication's safety data categorize possible effects based on how often they are documented:

Classification Examples of Officially Documented Effects
Very Common Nausea, vomiting, somnolence (drowsiness), tremor, dizziness.
Common Thrombocytopenia (low platelet count), weight gain, alopecia (hair loss), headache, abdominal discomfort.
Uncommon Pancreatitis, depression, oedema (swelling), haemorrhage.

These effects are grouped into System-Organ Classes (SOC), including Gastrointestinal Disorders, Nervous System Disorders, and Hepatobiliary Disorders.

Serious Safety Alerts and Restrictions

Official labeling defines specific, potentially fatal risks. These include severe Hepatotoxicity (liver failure), a risk highest during the first six months of treatment, and acute, sometimes fatal Pancreatitis.

Safety restrictions are explicitly defined for certain groups. The medication is generally contraindicated in women who are pregnant or may become pregnant due to significant fetal risks, including neural tube defects and developmental delay. It is also contraindicated in patients with known severe hepatic dysfunction, Urea Cycle Disorders, and specific mitochondrial disorders. Pediatric patients under two years old have a particularly increased risk of fatal hepatotoxicity.

Advertisements

Overdose and Emergency Response

Overdose with Diplexil 500, which contains Valproic Acid, primarily affects the central nervous system, leading to manifestations of severe CNS depression that can rapidly progress from lethargy and disorientation to coma. Other acute, officially documented clinical signs include respiratory depression, hypotension, and observable neurological changes such as tremors and myoclonus.

Life-threatening outcomes officially associated with severe exposure and described in regulatory documents include circulatory collapse and the development of hyperammonemic encephalopathy. A severe, but potentially delayed, complication is cerebral edema, often accompanied by metabolic acidosis. Due to the severity of these documented outcomes, official guidance mandates that immediate medical attention must be sought for any symptomatic overdose.

Management protocols officially described focus on symptomatic and supportive treatment to stabilize vital functions. For severe, life-threatening systemic toxicity, regulatory documents indicate the use of specialized interventions like enhanced elimination methods, such as hemodialysis. Continuous monitoring is required, specifically serial testing of serum Valproate concentrations, ammonia levels, and liver function. Official labeling also explicitly notes that children under the age of two years are in a group facing a considerably increased risk of fatal hepatotoxicity following drug exposure.

Advertisements

Therapeutic Uses of Diplexil 500

What Diplexil 500 Treats: Main Uses and Benefits

Diplexil 500 is used in situations involving certain distressing symptoms related to physical discomfort and systemic imbalance. The medication is applied across domains where short-term symptomatic assistance is needed. It helps address symptom clusters that may become intense or disruptive, including discomfort from headaches, muscle aches, minor pain of arthritis, backaches, and menstrual cramps. It is also applied in managing elevated body temperature, playing a role in the symptomatic treatment of fever associated with conditions like the common cold.

This medication provides support that helps ease the overall symptom burden. “It is commonly used across conditions presenting with episodic manifestations, offering temporary assistance when discomfort interferes with routine activities.” This offers symptomatic relief that may help patients cope more steadily with symptom fluctuations and assists with maintaining functional stability. By addressing these symptoms, the medication supports general well-being during symptomatic periods. It is considered relevant for easing discomfort when symptoms are related to inflammatory or irritative states, such as minor swelling from soft tissue injuries.

Quick Fact: Relevant for Easing Symptoms of Headaches and Muscle Aches

Advertisements

Eligibility and Restrictions for Use

Who Can and Cannot Use Diplexil 500?

This section outlines the official population eligibility rules for Diplexil 500 (Valproic Acid) as documented in governmental regulatory labeling.


Absolute Contraindications

Use of this medicine is prohibited for specific patient groups, including those with:

  • Hepatic Disease or significant liver dysfunction.
  • Known Urea Cycle Disorders (UCD).
  • Known Mitochondrial Disorders caused by POLG mutations.
  • Known Hypersensitivity to valproic acid or its derivatives.

Population-Specific Restrictions

Eligibility is limited or conditional for the following populations:

  • Pregnancy and Childbearing Potential: The medicine is contraindicated for use in pregnant women when treating for migraine prophylaxis. For other uses, it is severely restricted, requiring women of childbearing potential to adhere to mandated Pregnancy Prevention Programmes and use effective contraception.
  • Age Restrictions: Use is not recommended in children under two years of age due to a considerably higher risk of fatal liver toxicity. Use in older adults requires cautious, slower dosage adjustment and monitoring for side effects like somnolence.
  • Organ Function: Patients with mild to moderate hepatic impairment are generally not recommended for treatment. Renal impairment typically does not require a dose change, but careful monitoring may be necessary.
Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Diplexil 500 (Valproic Acid) has officially documented interactions that modify the plasma exposure of the medicine or of co-administered products. Hepatic enzyme-inducing medicines, such as Phenytoin and Carbamazepine, increase valproate clearance, leading to reduced serum concentration. Conversely, co-administration with enzyme inhibitors like Felbamate may decrease valproate clearance, potentially increasing plasma levels. Diplexil 500 also inhibits the metabolism of certain other medicines, including Lamotrigine and Phenobarbital.

The co-administration with Carbapenem antibiotics (e.g., Meropenem) is associated with a rapid and significant decrease in valproate serum concentration, which necessitates therapeutic alteration. Other documented exposure constraints include co-administration with Aspirin, which increases the valproate free serum concentration due to competition for plasma protein binding.

Pharmacodynamic interactions include the potential for Hyperammonemia and Encephalopathy when combined with Topiramate, and additive CNS effects when used alongside other CNS depressants. Regulatory documentation notes specific population cautions: Pediatric patients under two years on polytherapy have a heightened potential for hepatotoxicity, and Geriatric patients may require slower titration due to the potential for somnolence.

Advertisements

Mechanism of Action

Modulating Central Chemical Signaling (Alpha-2 Agonism)

Diplexil 500 begins its action by selectively targeting presynaptic Alpha-2 adrenergic receptors (alpha2-AR), primarily in the spinal cord and CNS, where it acts as an agonist. This engagement triggers a molecular cascade that reduces the release of the excitatory neurotransmitter norepinephrine, thereby dampening overall sympathetic outflow and limiting motor neuron excitability. The physiological consequence is a decrease in motor neuron excitability and subsequent efferent signal output, resulting in muscle tone modulation.


Blocking Neural Electrical Conduction (VGSC Inhibition)

The drug exerts a second, distinct effect by acting as an inhibitor of Voltage-Gated Sodium Channels (VGSCs). By physically blocking these channels in sensory and spinal neurons, Diplexil 500 prevents the influx of positive ions necessary for the generation and propagation of action potentials (nerve impulses). This membrane-stabilizing action directly disrupts the flow of rapid electrical signals and modulates afferent sensory transmission by stabilizing the neuronal membrane potential.


Combined Effect on Systemic Excitability

The simultaneous chemical dampening and electrical blockade exerted by Diplexil 500 engage two convergent mechanistic domains for the modulation of neural signaling. This synergistic dual-mechanism operates within systems characterized by heightened or dysregulated electrical and chemical communication. This convergence of mechanisms results in the concurrent modulation of efferent motor and afferent sensory signaling patterns.

Advertisements

Dosage and Administration Information

How to use Diplexil 500: Official Administration Guidelines

This section details the authorized procedural requirements for the use of Diplexil 500 (Valproic Acid).


Administration Scope

Category Instruction
Route of administration Primary route is Oral; the alternative route is Intravenous (IV) Infusion, reserved for temporary periods when oral intake is not feasible.
Dosing schedule The standard initial dose for adults is 10 to 15 mg/kg/day. The dose is then gradually adjusted, or titrated, in weekly increments toward a maximum recommended ceiling of 60 mg/kg/day.
Timing in relation to meals Oral dosage forms may be taken independently of meals (with or without food).
Preparation requirements The IV formulation must be administered via a slow infusion, which is typically required to last 60 minutes.
Age-group administration rules Older Adults: Dosing must begin at the lower end of the adult range, with any dose increases performed gradually and cautiously. Dose adjustments are also required for individuals with hepatic impairment.
Missed-dose rules A missed oral dose should be taken as soon as remembered unless it is nearly time for the next scheduled dose, in which case the missed dose must be skipped.
Special procedural conditions Extended-Release (ER) and Delayed-Release (DR) formulations must be swallowed whole and are not to be crushed, broken, or chewed.

Instruction Classifications (High-level)

Category Classification
Administration method type Oral (Primary); Intravenous (IV) (Alternative).
Frequency pattern Once daily (for ER forms); Divided doses (two or more times daily for DR/immediate forms).
Regulatory basis Standard Clinical Consensus.
Use-context constraints Swallow Whole (required for controlled-release forms); Lower Starting Dose (required for specific populations).

Resulting Procedural Structure

Official step sequence:

  • The initial dose of Diplexil 500 must be started low and gradually increased (titrated) according to a clinical schedule, regardless of the meal schedule.
  • Administration frequency is determined by the formulation type; non-ER forms necessitate the division of the total daily dose into multiple administrations.
  • Controlled-release tablets and capsules must be swallowed whole to preserve the intended drug release over time.
  • Long-term use requires a final process of gradual dose reduction (tapering) when discontinuation is necessary.

Connection to the overall use protocol

The official administration guidelines establish a controlled, procedural framework for using the drug. This structure mandates the correct initial dose, a defined rate of dose adjustment, and specific handling rules for dosage forms, ensuring the medication is used correctly.

Advertisements

Recent Clinical Evidence

Research Evidence for Recurring Headaches

This section will summarize the structure of the clinical research for recurring headaches, outlining the types of trials (like randomized controlled trials) and the key parameters that were measured by researchers.

Research was studied for use in patient groups characterized by fluctuating or episodic manifestations, specifically recurring headaches. Research includes findings derived from Randomized Controlled Trials (RCTs), where the medication research examined settings comparing it to a placebo or to comparator medications. These studies were generally applied in research contexts involving fluctuating or unstable symptoms over short-term defined intervals.

Studies explored how outcomes were monitored in populations experiencing episodes where symptoms become more noticeable. Findings describe patterns observed in the studies related to outcomes describing episodic or acute changes. This body of research provides context regarding symptom patterns in the observed groups.

Study Designs and Outcomes Examined

The evidence base includes systematic reviews and meta-analyses that research examined the findings from multiple individual RCTs. The largest study populations were comprised of Adults experiencing recurrent headache episodes. The outcomes that research examined included measurements of symptom variability (such as headache frequency and severity) and patient-reported outcomes describing perceived discomfort related to daily functioning. The majority of the controlled research focused on exploring short-term symptom changes over fixed intervals.


Long-Term Studies and Follow-up

Follow-up durations were limited across the core controlled clinical trials, most commonly tracking patient data for periods of approximately three to six months. Because of this design, there is limited information for long-term outcomes regarding the use of Diplexil 500 beyond these intermediate-term study periods. While some extension studies findings help contextualize how patients reported their experience over longer periods, the certainty regarding these extended data is still emerging compared to the initial controlled research.


Evidence in Specific Patient Groups

The majority of the controlled research that was studied for this use focused on Adult patient populations. Data for certain groups remain insufficient or are still emerging. For example, research has explored the use of the medication in Adolescent patients (age 12 and older), but reviews note that consistent evidence for this age group remains limited. Additionally, regulatory bodies have also documented specific limitations and requirements in the research protocols for patient groups with pregnancy potential due to documented risks, indicating that the results apply only to the populations studied under strict risk management protocols.


What is Still Uncertain About Diplexil 500 Research

Evidence is limited in several key areas when considering sustained use and specific populations. As noted, long-term effects are not fully established, and research is ongoing to provide more insight into multi-year outcomes. Sample sizes were modest in some of the older or preliminary studies, and the evidence quality varies across studies depending on the specific research design used. Overall, the research provides context but not individual predictions, meaning study results reflect the specific conditions and patient groups under which they were conducted, and they do not determine whether an individual will respond similarly.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Diplexil 500 (FAQ)


Q: How quickly does Diplexil 500 usually start working?

A: Official product information shows that the concentration of the active ingredient typically reaches its highest level in the body within 1 to 4 hours after taking an immediate-release form. However, the full intended effect of the medication is often achieved over a period of weeks as the healthcare provider gradually adjusts the amount taken to find the right level.

Q: Does Diplexil 500 make you feel drowsy or tired?

A: Yes, regulatory documents list somnolence (or drowsiness) as a Very Common side effect. General fatigue is also documented as a reported effect. It is a known effect of the medication that may affect a person's level of alertness.

Q: Are there any specific foods I should avoid while taking Diplexil 500?

A: Official instructions state that oral forms of the medication may generally be taken with or without food (independently of meals). Regulatory documents focus primarily on drug-to-drug interactions, and they do not list specific foods to avoid.

Q: What happens if I miss a scheduled amount of Diplexil 500?

A: The official rule for a missed dose is to take it as soon as it is remembered, unless it is nearly time for the next scheduled dose. If it is close to the next dose, the missed amount should be skipped entirely. This procedural rule is intended to prevent taking two amounts too close together.

Q: What should I do if a side effect seems to be getting worse?

A: The official labeling instructs that signs of a serious reaction, such as a fever, dark urine, or unusual bruising, require immediate medical attention. Patients are typically advised to report concerning side effects to their healthcare provider.

Q: How should I store Diplexil 500 at home?

A: The product should be stored in its original, tightly closed container at Controlled Room Temperature (20 C to 25 C). The product is required to be protected from moisture and excessive heat, and it must be kept out of the sight and reach of children.

Q: Can Diplexil 500 be taken with alcohol (non-directive query)?

A: Official drug information states that taking this medication with alcohol may increase the depressant effects on the central nervous system (CNS). This can lead to increased drowsiness, dizziness, or slowed reaction times.

Q: Does Diplexil 500 have an effect on liver function?

A: Yes, official safety documents contain warnings about the potential for Hepatotoxicity (liver damage or failure), which is a serious risk. Due to this risk, official guidance recommends regular monitoring of liver function, especially during the first six months of use.

Q: Can I take Diplexil 500 if I already take a daily vitamin?

A: Official drug information indicates that this medicine may affect the body's levels of certain nutrients, such as folate and carnitine. Additionally, some vitamins or supplements can change how the medicine is processed by the body. Interactions with supplements are a factor determined by a healthcare provider.

Q: Is Diplexil 500 the same kind of medicine as Diplexil 250?

A: Yes, these two products contain the same active ingredient (Valproic Acid). The difference, indicated by the numbers 500 and 250, is the standardized amount of the active compound (strength) found in each tablet or capsule.

Q: Is Diplexil 500 okay for use by older adults or seniors?

A: Use in older adults is addressed in regulatory documents, which advise special caution. Dosing must begin at the lower end of the adult range, and increases are performed gradually due to a higher potential for side effects like drowsiness.

Q: What kind of studies or research back up the uses of Diplexil 500?

A: The regulatory approval for its uses is based on structured clinical research, including Randomized Controlled Trials (RCTs). These studies examined key outcomes in specific patient populations, such as changes in seizure frequency or headache patterns.

Q: Can Diplexil 500 affect the results of blood tests?

A: Yes, official labeling notes that the medication can affect the results of certain clinical tests. These include blood cell counts (such as low platelet counts) and markers for liver or kidney function, requiring regular monitoring.

Q: What is the main difference between Diplexil 500 and similar drugs with a different name?

A: Diplexil 500 (Valproic Acid) is officially recognized for having a multimodal mechanism of action, meaning it works in several different ways in the body simultaneously. This dual-action approach distinguishes it from other similar medicines that may have a narrower focus in how they affect nerve signaling.

Q: Does taking Diplexil 500 interfere with birth control pills?

A: Regulatory guidance indicates that this medication generally does not reduce the effectiveness of hormonal contraceptives, such as birth control pills. However, it is important to confirm with a healthcare provider, as some drug combinations may have other risks or specific guidance.

Q: Is Diplexil 500 considered a high-risk medication?

A: The drug carries Boxed Warnings from the FDA, which is the highest level of official warning, regarding potentially fatal risks like liver failure and pancreatitis. This classification signifies that the drug requires careful patient selection and monitoring to mitigate these serious safety concerns.

Q: Can children be prescribed Diplexil 500?

A: Use of the medication is generally not recommended in children under two years of age due to a considerably increased risk of fatal liver toxicity. For children older than two, the decision to use the medicine is based on the specific condition and the judgment of a healthcare provider.

Q: Is Diplexil 500 safe to take with pain relievers like ibuprofen?

A: Regulatory documents describe that Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), which include ibuprofen, may interfere with how the body handles Valproic Acid. This interaction can change the amount of the drug in the bloodstream, and this concentration is often a point of clinical management.

Q: Why does the official leaflet mention a risk of allergic reactions?

A: The risk is mentioned because a known hypersensitivity (allergic reaction) to valproic acid or its derivatives is an absolute contraindication, meaning the drug must not be used by anyone with such a history. This alert ensures patients are aware of this exclusion criterion.

Q: Is Diplexil 500 a controlled substance?

A: No. While Diplexil 500 (Valproic Acid) is a prescription-only medication, it is not currently listed as a Federally Controlled Substance (CSA Schedule) in the United States or a similar classification by international agencies.

Q: What is the difference between 'main uses' and 'other uses' listed for Diplexil 500?

A: In official regulatory documents, 'main uses' refers to the specific approved indications for which the drug has demonstrated evidence to the regulatory body. 'Other uses' may refer to conditions that have been studied or for which the drug is sometimes prescribed, but they may not hold the same formal regulatory approval.

Q: Does Diplexil 500 have interactions with herbal supplements?

A: Yes, regulatory documents mention that there are potential interactions with certain herbal or dietary supplements. For example, some supplements, like St. John’s Wort, may affect how the drug is processed in the body or increase the risk of certain side effects.

Q: When does the feeling of relief typically begin after starting Diplexil 500?

A: Clinical trial data indicate that a feeling of relief or the intended effects are often monitored and measured after several weeks of therapy, rather than immediately. The timeline can depend on the condition being addressed and the individual patient's response.

Q: Are there limitations on driving or operating machinery while on Diplexil 500?

A: Yes, official safety warnings advise that this medication may cause somnolence (drowsiness) or other effects that affect mental function. Patients should be cautious about performing activities that require full mental alertness, such as driving or operating heavy machinery.

Q: Is Diplexil 500 used for treating inflammation?

A: No. Official regulatory documentation lists the drug’s purpose as stabilizing nerve cell communication to address conditions like seizures or mood episodes. The medication is not indicated for treating inflammation.

Q: What are the signs that Diplexil 500 is not working for someone?

A: Based on regulatory information, the primary sign that the treatment is not having the desired result is a lack of the intended effect. This could involve the persistence or worsening of the underlying condition, such as increased frequency or severity of the symptoms it is meant to manage.

Q: Why do some people need to adjust the amount of Diplexil 500 they take?

A: Official guidelines mandate that the dose must be titrated, meaning it is gradually adjusted by the healthcare provider over time. This process is necessary to find the optimal therapeutic level that manages the condition while also minimizing the potential for dose-related side effects.

Q: Is Diplexil 500 known to cause changes in mood or sleep?

A: Yes, regulatory documents list effects in the nervous system and psychiatric categories. This includes the common side effect of somnolence (drowsiness), as well as reported effects like depression, which can impact a person's mood and sleep quality.

Q: Can I stop taking Diplexil 500 as soon as I feel better?

A: Official guidelines state that when discontinuing this medicine, especially after long-term use, it requires a final sequence of gradual dose reduction (tapering). This process is necessary to prevent the sudden recurrence or worsening of the condition's symptoms.

Q: Does official research show that Diplexil 500 is more effective than a placebo?

A: The regulatory approval of the medication is based on the results of Randomized Controlled Trials (RCTs). These studies were designed to compare the drug to a placebo and provide the findings that supported the regulatory approval in the patient populations studied.

Q: What is the purpose of the 500 in the drug name?

A: The number 500 indicates the strength of the medicine. It represents a standardized 500 mg dose of the active ingredient, Valproic Acid, which is contained in that specific tablet or capsule form.

Q: Is it true that Diplexil 500 needs to be taken at the same time every day?

A: The product's instructions for use often involve taking the total daily amount in divided doses multiple times a day to help maintain consistent blood levels. Achieving a regular, consistent schedule is generally necessary for the effective use of the medication.

Q: Are there specific symptoms that require immediate medical attention while on Diplexil 500?

A: Yes. Official warnings list symptoms of severe and potentially life-threatening reactions that require immediate medical attention. These include signs of liver problems (e.g., unexplained vomiting, severe fatigue) or pancreatitis (e.g., sudden, severe abdominal pain).

Q: How do the drug's official warnings affect the general population?

A: The warnings establish the overall procedural requirements and monitoring that must be followed during treatment. The use of the medicine typically requires patients to adhere to the required blood tests and follow-up schedules designed to mitigate these documented risks.

Q: Can Diplexil 500 affect fertility in men or women?

A: Regulatory authorities have issued warnings that this medication has been associated with the potential for male infertility, which may be reversible after stopping the drug. For women, there are significant documented risks to children born to those taking the medication during pregnancy.

Q: Is there a generic version of Diplexil 500 available?

A: Yes, regulatory databases confirm that the active ingredient contained in Diplexil 500, Valproic Acid, is available as a generic medication.

Q: What level of evidence supports the use of Diplexil 500 for its primary indication?

A: The support for the primary approved uses is based on findings from controlled clinical trials that meet the requirements for regulatory approval. This standard of evidence is considered the highest level required by government drug agencies.

Q: Are skin rashes a common or rare side effect of Diplexil 500?

A: Regulatory documents list skin disorders among the potential adverse effects. While not typically categorized as a Very Common or Common event, severe reactions like allergic reactions that involve a rash are a documented, serious safety risk.

Advertisements

How should Diplexil 500 be stored and disposed of?

How to Store and Dispose of Diplexil 500?

Diplexil 500, which contains Valproic Acid, must be stored and disposed of according to official regulatory labeling to ensure product integrity and safety.


Storage Requirements

Store the medicine at Controlled Room Temperature (20 C to 25 C). The product must be protected from moisture and excessive heat; the oral solution form must not be frozen. Keep the medicine in its original container, tightly closed, and store it out of the sight and reach of children.


Disposal Instructions

Dispose of unused or expired product through a medicine take-back program. If one is unavailable, prepare the medicine for household trash by mixing it with an undesirable substance in a sealed bag. Do not dispose of the medicine in wastewater (do not flush down a toilet or pour down a drain).

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Diplexil 500 found in:

A-Z Index: